(Q33391729)

26 July 2017

A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer (English)

1 reference

26 July 2017

1 reference

1 reference

10

Kentaro Yasuchika

1 reference

26 July 2017

11

Kojiro Taura

1 reference

26 July 2017

23

Etsuro Hatano

1 reference

26 July 2017

22

Shinji Uemoto

1 reference

26 July 2017

19

Tsutomu Chiba

1 reference

26 July 2017

Masashi Kanai

1

1 reference

26 July 2017

Kenichi Yoshimura

2

1 reference

26 July 2017

Takehiko Tsumura

3

1 reference

26 July 2017

Masanori Asada

4

1 reference

26 July 2017

Chihiro Suzuki

5

1 reference

26 July 2017

Miyuki Niimi

6

1 reference

26 July 2017

Shigemi Matsumoto

7

1 reference

26 July 2017

Takafumi Nishimura

8

1 reference

26 July 2017

Takashi Nitta

9

1 reference

26 July 2017

Yukiko Mori

12

1 reference

26 July 2017

Akihiko Hamada

13

1 reference

26 July 2017

Naoya Inoue

14

1 reference

26 July 2017

Shinsuke Tada

15

1 reference

26 July 2017

Kazuhiro Yanagihara

16

1 reference

26 July 2017

Shujiro Yazumi

17

1 reference

26 July 2017

Yukio Osaki

18

1 reference

26 July 2017

Iwao Ikai

20

1 reference

26 July 2017

Masanori Fukushima

21

1 reference

26 July 2017

2 September 2010

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

1 reference

26 July 2017

67

1 reference

26 July 2017

6

1 reference

26 July 2017

1429-1434

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-010-1443-5

26 July 2017

0 references

cites work

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Cholangiocarcinoma: Current concepts and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Biliary tract cancers: current concepts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Phase II study of S-1 in patients with advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

Experimental study of combination therapy with S-1 against pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1443-5

10.1007/S00280-010-1443-5

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference